{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:31:41Z","timestamp":1791329501262,"version":"4.3.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4265,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1093\/annonc\/mdm516","type":"journal-article","created":{"date-parts":[[2007,12,12]],"date-time":"2007-12-12T04:46:24Z","timestamp":1197434784000},"page":"711-716","source":"Crossref","is-referenced-by-count":37,"title":["First-line single-agent cetuximab in patients with advanced colorectal cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"A.","family":"Pessino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Artale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sciallero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guglielmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.C.","family":"Andreotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mammoliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Comandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Caprioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bennicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Andretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sobrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm516_bb0010","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.1989.7.10.1419","article-title":"The modulation of fluorouracil by leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group","volume":"7","author":"Petrelli","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0015","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0020","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2005.17.749","article-title":"Systemic therapy for metastatic colorectal cancer: current options, current evidence","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0025","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.0007-1323.2001.01821.x","article-title":"Resection rate and effect of post-operative chemotherapy on survival after surgery for colorectal liver metastases","volume":"88","author":"Figueras","year":"2001","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdm516_bb0040","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.1992.10.6.904","article-title":"Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group","volume":"10","author":"Nordic Gastrointestinal Tumor Adjuvant Group","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0045","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/sj.bjc.6602841","article-title":"A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer","volume":"93","author":"Ackland","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm516_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(03)12461-0","article-title":"Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial","volume":"361","author":"Maughan","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm516_bb0055","first-page":"166s","article-title":"Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study","volume":"25","author":"Maindrault-Goebel","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0060","first-page":"147s","article-title":"Alternating versus continuous FOLFIRI in advanced colorectal cancer: a randomised GISCAD trial","volume":"24","author":"Labianca","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm516_bb0070","first-page":"166s","article-title":"Sequential compared to combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study","volume":"25","author":"Punt","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm516_bb0080","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with chemorefractory colorectal cancer that express the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0085","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0090","author":"Jonker","year":"2007","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdm516_bb0095","first-page":"164s","article-title":"Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0100","unstructured":"National Cancer Institute Intergroup CALGB 80405. Phase III randomized study of cetuximab and\/or bevacizumab in combination with either oxaliplatin, fluorouracil, and leucovorin calcium (FOLFOX) OR irinotecan hydrochloride, fluorouracil, and leucovorin calcium (LIRI) in patients with previously untreated metastatic adenocarcinoma of the colon or rectumhttp:\/\/www.cancer.gov\/search\/ViewClinicalTrials.aspx?cdrid=455161&version=HealthProfessional&protocolsearchid=3793937 (27 December 2006, date last accessed)"},{"key":"10.1093\/annonc\/mdm516_bb0105","first-page":"172s","article-title":"Cetuximab plus 5-FU\/FA\/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study","volume":"25","author":"Bokemeyer","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0110","first-page":"252s","article-title":"Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC)","volume":"22","author":"Cunningham","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdm516_bb0115","first-page":"ix114","article-title":"Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a TTD phase II study","volume":"17","author":"Sastre","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0125","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Lievre","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm516_bb0130","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2007.11.5956","article-title":"Epidermal growth factor receptor gene copy-number and clinical outcome of metastatic colorectal cancer treated with panitumumab","volume":"25","author":"Sartore-Bianchi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0135","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1158\/0008-5472.CAN-06-1000","article-title":"Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib","volume":"66","author":"Cunningham","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm516_bb0140","first-page":"127","article-title":"Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody EMD 72000 administered every three weeks. A phase I pharmacokinetic\/pharmacodynamic study to define the optimal biological dose","volume":"23","author":"Salazar","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0145","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1200\/JCO.2005.09.100","article-title":"Molecular determinants of cetuximab efficacy","volume":"23","author":"Valbohmer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0150","first-page":"18s","article-title":"Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab","volume":"24","author":"Zhang","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm516_bb0155","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","article-title":"Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies","volume":"67","author":"Benvenuti","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm516_bb0160","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1200\/JCO.2004.02.154","article-title":"Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation","volume":"22","author":"Nagasaka","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419414403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419414403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/4\/711\/579478\/mdm516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T13:24:38Z","timestamp":1582205078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419414403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0923753419414403"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm516","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}